• Profile
Close

Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial

British Journal of Ophthalmology Oct 07, 2020

Denis P, Hirneiß C, Durr GM, et al. - In this prospective, multicentre, first-in-human, single-arm interventional study, researchers sought to analyze the safety and effectiveness of the stand-alone implantation of the MINIject (iSTAR Medical, Wavre, Belgium) supraciliary, microinvasive glaucoma drainage device in patients with medically uncontrolled open-angle glaucoma. This investigation assessed stand-alone, ab interno implantation in 25 patients of a 5 mm long uveoscleral device made of STAR biocompatible material, which is a soft, microporous, flexible silicone. The mean baseline IOP was 23.2 ± 2.9 mmHg on 2.0 ± 1.1 glaucoma medication ingredients and declined to 13.8 ± 3.5 mmHg (−40.7% decrease) on 1.0 ± 1.3 medications 2 years after implantation. This first-in-human study on the stand-alone implantation of the MINIject supraciliary drainage system indicates encouraging IOP-lowering outcomes and reduction of medication over 24 months with some adverse events.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay